Literature DB >> 28147376

Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects.

Christian Hampel1, Dietmar Betz, Maximilian Burger, Christoph Nowak, Monika Vogel.   

Abstract

INTRODUCTION: The study aimed to evaluate the efficacy and safety of solifenacin in older patients with overactive bladder (OAB).
MATERIALS AND METHODS: Observational data on patients aged ≥70 years and the prescribed flexible dose of solifenacin for OAB were collected at 294 offices of German general practitioners. Baseline and week 12 data included type and severity of OAB symptoms, adverse events, quality of life, and change in cognitive function per Mini Mental State Examination (MMSE).
RESULTS: Mean age of 774 patients was 78 ± 6 years. A decrease was observed in all OAB symptoms including a reduction of urinary urgency and micturition, each by 4 episodes per 24 h. No change in mean MMSE scores was apparent at week 12. Adverse events and treatment discontinuations were low at 5.8 and 0.5%, respectively.
CONCLUSION: Solifenacin was well-tolerated while OAB symptoms declined at week 12. No relevant effect of solifenacin on cognitive function was observed in this elderly population.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28147376     DOI: 10.1159/000455257

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

1.  Hyperpolarization-Activated Cyclic Nucleotide-Gated Non-selective (HCN) Ion Channels Regulate Human and Murine Urinary Bladder Contractility.

Authors:  Felix Mader; Steffen Müller; Ludwig Krause; Armin Springer; Karoline Kernig; Chris Protzel; Katrin Porath; Simone Rackow; Tristan Wittstock; Marcus Frank; Oliver W Hakenberg; Rüdiger Köhling; Timo Kirschstein
Journal:  Front Physiol       Date:  2018-06-19       Impact factor: 4.566

2.  Risk of delirium associated with antimuscarinics in older adults: A case-time-control study.

Authors:  Prasad S Nishtala; Te-Yuan Chyou
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-05-25       Impact factor: 2.732

Review 3.  Pharmacology of the lower urinary tract: update on LUTS treatment.

Authors:  Pedro Abreu-Mendes; João Silva; Francisco Cruz
Journal:  Ther Adv Urol       Date:  2020-05-13

Review 4.  Treatment of bladder dysfunction with solifenacin: is there a risk of dementia or cognitive impairment?

Authors:  L P Dantas; A R C C Forte; B C Lima; C N S Sousa; E C Vasconcelos; P H C Lessa; R F Vieira; M C A Patrocínio; S M M Vasconcelos
Journal:  Braz J Med Biol Res       Date:  2022-01-25       Impact factor: 2.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.